Crossmark

Differential effects of d- and l-enantiomers of govadine on distinct forms of cognitive flexibility and a comparison with dopaminergic drugs

Published Online: 2021-01-11

Published Print: 2021-04

Authors

Dalton, Gemma L.

Floresco, Stan B. https://orcid.org/0000-0002-5633-243X
Phillips, Anthony G.
Funding

Funding for this research was provided by:

Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-04295)

Natural Sciences and Engineering Research Council of Canada (RGPIN- 2016- 043)
License Information

Text and Data Mining valid from 2021-01-11

Version of Record valid from 2021-01-11
More Information

Article History

Received: 22 September 2020

Accepted: 21 December 2020

First Online: 11 January 2021

Compliance with ethical standards

:

: AGP declares a patent related to the use of d-govadine to enhance dopamine function in the prefrontal cortex (tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric, and neurodegenerative diseases; US20150306092). AGP also holds shares in Resilience Biosciences Inc., Canada.

Document is current